ARTICLE | Clinical News
XOMA 358: Additional Ph II data
March 17, 2017 1:03 PM UTC
Additional data from an open-label, international Phase II trial in 14 patients ages 12-37 with hypoglycemia associated with congenital hyperinsulinism showed that single doses of IV XOMA 358 reduced ...
BCIQ Company Profiles
BCIQ Target Profiles